These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 19030860)

  • 1. Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction.
    Kumar G; Lau H; Laskin O
    Cancer Chemother Pharmacol; 2009 May; 63(6):1171-5. PubMed ID: 19030860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro assessment of cytochrome P450 inhibition and induction potential of felotaxel (SHR110008).
    Ding Y; Jia Y; Lu C; Liu W; Yang J; Song Y; Zhu Y; Yang L; Ding L; Wen A
    Biomed Pharmacother; 2012 Jun; 66(4):318-21. PubMed ID: 22397757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.
    Parkinson A; Mudra DR; Johnson C; Dwyer A; Carroll KM
    Toxicol Appl Pharmacol; 2004 Sep; 199(3):193-209. PubMed ID: 15364537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities.
    Doehmer J; Weiss G; McGregor GP; Appel K
    Toxicol In Vitro; 2011 Feb; 25(1):21-7. PubMed ID: 20828605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytes.
    Ghosal A; Hapangama N; Yuan Y; Lu X; Horne D; Patrick JE; Zbaida S
    Biopharm Drug Dispos; 2003 Dec; 24(9):375-84. PubMed ID: 14689466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.
    McGinnity DF; Berry AJ; Kenny JR; Grime K; Riley RJ
    Drug Metab Dispos; 2006 Aug; 34(8):1291-300. PubMed ID: 16679385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine.
    Chen Y; Liu L; Laille E; Kumar G; Surapaneni S
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):995-1000. PubMed ID: 20119716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin.
    Gan J; Liu-Kreyche P; Humphreys WG
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):51-6. PubMed ID: 21594721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation.
    Valles B; Schiller CD; Coassolo P; De Sousa G; Wyss R; Jaeck D; Viger-Chougnet A; Rahmani R
    Drug Metab Dispos; 1995 Oct; 23(10):1051-7. PubMed ID: 8654192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and metabolism of a cysteinyl leukotriene-1 receptor antagonist from the heterocyclic chromanol series in rats: in vitro-in vivo correlation, gender-related differences, isoform identification, and comparison with metabolism in human hepatic tissue.
    Kuperman AV; Kalgutkar AS; Marfat A; Chambers RJ; Liston TE
    Drug Metab Dispos; 2001 Nov; 29(11):1403-9. PubMed ID: 11602515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesol as an inhibitor and substrate for rabbit liver microsomal P450 enzymes.
    Raner GM; Muir AQ; Lowry CW; Davis BA
    Biochem Biophys Res Commun; 2002 Apr; 293(1):1-6. PubMed ID: 12054554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of human liver cytochrome P450 enzymes involved in the metabolism of a new H+/K+-ATPase inhibitor KR-60436.
    Ji HY; Lee HW; Kim HH; Choi JK; Lee HS
    Toxicol Lett; 2005 Jan; 155(1):103-14. PubMed ID: 15585365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist.
    Takusagawa S; Miyashita A; Iwatsubo T; Usui T
    Xenobiotica; 2012 Dec; 42(12):1187-96. PubMed ID: 22834478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities.
    Dixit V; Hariparsad N; Desai P; Unadkat JD
    Biopharm Drug Dispos; 2007 Jul; 28(5):257-62. PubMed ID: 17443647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inhibitory effect of tannic acid on cytochrome P450 enzymes and NADPH-CYP reductase in rat and human liver microsomes.
    Yao HT; Chang YW; Lan SJ; Yeh TK
    Food Chem Toxicol; 2008 Feb; 46(2):645-53. PubMed ID: 17950511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP.
    Yamane M; Kawashima K; Yamaguchi K; Nagao S; Sato M; Suzuki M; Honda K; Hagita H; Kuhlmann O; Poirier A; Fowler S; Funk C; Simon S; Aso Y; Ikeda S; Ishigai M
    Xenobiotica; 2015 Mar; 45(3):230-8. PubMed ID: 25350082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450.
    Sonesson A; Rasmussen BB
    Basic Clin Pharmacol Toxicol; 2011 Sep; 109(3):195-202. PubMed ID: 21496210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate.
    Venkatakrishnan K; von Moltke LL; Greenblatt DJ
    J Pharmacol Exp Ther; 2001 Apr; 297(1):326-37. PubMed ID: 11259560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of liposomal curcumin cytochrome p450 metabolism.
    Mach CM; Chen JH; Mosley SA; Kurzrock R; Smith JA
    Anticancer Res; 2010 Mar; 30(3):811-4. PubMed ID: 20393001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay.
    Brown HS; Wilby AJ; Alder J; Houston JB
    Drug Metab Dispos; 2010 Dec; 38(12):2139-46. PubMed ID: 20847136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.